Infovista Appoints industry veteran Andrew Miceli to lead US market
Joins as VP Sales for US to drive sales and services operations Paris, France –…
Month: May 2022
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended…
Bionomics Limited to Participate in Upcoming Investor Conferences
ADELAIDE, Australia, May 16, 2022 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX | ASX: BNO)…
Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress
Clinical trial sites open and enrolling patients in FDA and EMA registration-directed Phase III Part…
Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
GUANGZHOU, China, May 16, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the…
IDCM Rebrands to Klickl After 5 Years as Innovative Features like Contract Trading and Bridge Market Aim to Impress
Hong Kong, Hong Kong–(Newsfile Corp. – May 16, 2022) – IDCM has decided to rebrand…
Tam Jai International’s Adjusted Profit for the Year Rises by 17.8% to HK$165.5 Million
HONG KONG, May 16, 2022 – (ACN Newswire) – Tam Jai International Co. Limited (“TJI”…
AIDP’s Andy Khawaja Earns World’s Leaders Cover as a True Philanthropist
LOS ANGELES–(BUSINESS WIRE)–Artificial Intelligence Defense Platform, a technology start-up creating AI technology for a safer,…
The3rdBevCo Announces Their Qualification of a Regulation A+ Public Stock Offering
RONKONKOMA, N.Y.–(BUSINESS WIRE)–Noted beverage, supplement, and finance exec, and The3rdBevCo CEO Peter Scalise today announced…
BioAge Developing a Novel Class of Potent NLRP3 Inhibitors With Distinct Structural and Pharmacologic Properties for Inflammatory and Age-Related Diseases
New compounds specifically inhibit NLRP3 in mouse models and human cells Series includes orally active…
Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine
REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya Therapeutics, Inc., a fully integrated gene…
AI-Powered Retail Analytics Platform, Intelligence Node, Appoints Senior Executives & Advisory Board Members to Drive US Expansion
SAN FRANCISCO–(BUSINESS WIRE)–Global Retail Intelligence leader Intelligence Node announces several strategic hires to accelerate its…
JetBlue Urges Spirit Shareholders to Protect Their Interests and ‘Vote No’ on Frontier Transaction at Upcoming Spirit Special Meeting
JetBlue’s proposal offers Spirit’s shareholders and other stakeholders more value, more certainty and more opportunity…
MUFG Announces Shift in Expected Closing Date of the Sale of MUFG Union Bank to U.S. Bancorp to Second Half of CY2022
TOKYO & NEW YORK–(BUSINESS WIRE)–On September 21, 2021, MUFG and MUFG Bank, a core banking…
Kasten by Veeam Announces NEW Kasten K10 V5.0 with Enhanced Kubernetes Security, Streamlined CI/CD Pipelines and Ecosystem Advancements
New features and capabilities bolster Kubernetes security across the board, help apply shift-left security to…
With Transatel, NTT Rolls out New 5G IoT Service in the USA to Accelerate Connected Industries Transformation
PARIS–(BUSINESS WIRE)–Transatel – subsidiary of NTT since 2019 – announces the worldwide deployment of a…
MUFG Bank, Ltd. UK Regulatory Announcement: MUFG Announces Shift in Expected Closing Date of the Sale of MUFG Union Bank to U.S. Bancorp to Second Half of CY2022
TOKYO & NEW YORK–(BUSINESS WIRE)– Mitsubishi UFJ Financial Group, Inc. (MUFG) MUFG Bank, Ltd. MUFG…
The Nuvias Group Appointed Sole Distribution Partner for Armis across UK and DACH
Nuvias partners gain access to the entire Armis portfolio, addressing the considerable asset visibility market…
De nouvelles données de l’essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de PXT3003 chez les patients atteints de la maladie de Charcot-Marie-Tooth de type 1A après une durée totale de cinq ans d’essai clinique
De nouvelles données de l’essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de PXT3003 chez…
New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time
New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial,…